1. Home
  2. NDLS vs TENX Comparison

NDLS vs TENX Comparison

Compare NDLS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

N/A

Current Price

$13.74

Market Cap

68.7M

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.89

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
TENX
Founded
1995
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
71.1M
IPO Year
2013
2001

Fundamental Metrics

Financial Performance
Metric
NDLS
TENX
Price
$13.74
$1.89
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
26.2K
7.0M
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$1.31
52 Week High
$19.00
$19.40

Technical Indicators

Market Signals
Indicator
NDLS
TENX
Relative Strength Index (RSI) 42.95 26.18
Support Level $12.83 $1.31
Resistance Level $16.10 $2.43
Average True Range (ATR) 0.86 0.19
MACD -0.15 0.47
Stochastic Oscillator 15.92 37.11

Price Performance

Historical Comparison
NDLS
TENX

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: